|
1
|
Dawson SJ, Provenzano E and Caldas C:
Triple negative breast cancers: Clinical and prognostic
implications. Eur J Cancer. 45:(Suppl 1). S27–S40. 2009. View Article : Google Scholar
|
|
2
|
Reis-Filho JS and Tutt AN: Triple negative
tumours: A critical review. Histopathology. 52:108–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anders CK and Carey LA: Biology,
metastatic patterns and treatment of patients with triple-negative
breast cancer. Clin Breast Cancer. 9:(Suppl 2). S73–S81. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kapp AV, Jeffrey SS, Langerød A,
Børresen-Dale AL, Han W, Noh DY, Bukholm IR, Nicolau M, Brown PO
and Tibshirani R: Discovery and validation of breast cancer
subtypes. BMC Genomics. 7:2312006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mattie MD, Benz CC, Bowers J, Sensinger K,
Wong L, Scott GK, Fedele V, Ginzinger D, Getts R and Haqq C:
Optimized high-throughput microRNA expression profiling provides
novel biomarker assessment of clinical prostate and breast cancer
biopsies. Mol Cancer. 5:242006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu Z, Fan C, Oh DS, Marron JS, He X,
Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al: The
molecular portraits of breast tumors are conserved across
microarray platforms. BMC Genomics. 7:962006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-Rehim Abd DM, Ball G, Pinder SE, Rakha
E, Paish C, Robertson JF, Macmillan D, Blamey RW and Ellis IO:
High-throughput protein expression analysis using tissue microarray
technology of a large well-characterised series identifies
biologically distinct classes of breast cancer confirming recent
cDNA expression analyses. Int J Cancer. 116:340–350. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sorlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cascione L, Gasparini P, Lovat F, Carasi
S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, et
al: Integrated microRNA and mRNA signatures associated with
survival in triple negative breast cancer. PLoS One. 8:e559102013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma H, Morey R, O'Neil RC, He Y, Daughtry
B, Schultz MD, Hariharan M, Nery JR, Castanon R, Sabatini K, et al:
Abnormalities in human pluripotent cells due to reprogramming
mechanisms. Nature. 511:177–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Killian JK, Kim SY, Miettinen M, Smith C,
Merino M, Tsokos M, Quezado M, Smith WI Jr, Jahromi MS, Xekouki P,
et al: Succinate dehydrogenase mutation underlies global epigenomic
divergence in gastrointestinal stromal tumor. Cancer Discov.
3:648–657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sherman BT, da Huang W, Tan Q, Guo Y, Bour
S, Liu D, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID
Knowledgebase: A gene-centered database integrating heterogeneous
gene annotation resources to facilitate high-throughput gene
functional analysis. BMC Bioinformatics. 8:4262007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li S, Armstrong CM, Bertin N, Ge H,
Milstein S, Boxem M, Vidalain PO, Han JD, Chesneau A, Hao T, et al:
A map of the interactome network of the metazoan C. elegans.
Science. 303:540–543. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Freed-Pastor WA and Prives C: Mutant p53:
One name, many proteins. Genes Dev. 26:1268–1286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tennis M, Krishnan S, Bonner M, Ambrosone
CB, Vena JE, Moysich K, Swede H, McCann S, Hall P, Shields PG and
Freudenheim JL: p53 Mutation analysis in breast tumors by a DNA
microarray method. Cancer Epidemiol Biomarkers Prev. 15:80–85.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanby AM: Aspects of molecular phenotype
and its correlations with breast cancer behaviour and taxonomy. Br
J Cancer. 92:613–617. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ,
Li J, Ma B and Song X: CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1
protein expressions as predictors of pathological complete response
to neoadjuvant chemotherapy in triple-negative breast cancer
patients. Med Oncol. 28:(Suppl 1). S129–S134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishimura R and Arima N: Is triple
negative a prognostic factor in breast cancer? Breast Cancer.
15:303–308. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Avery-Kiejda KA, Morten B, Wong-Brown MW,
Mathe A and Scott RJ: The relative mRNA expression of p53 isoforms
in breast cancer is associated with clinical features and outcome.
Carcinogenesis. 35:586–596. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Caradec J, Sirab N, Revaud D, Keumeugni C
and Loric S: Is GAPDH a relevant housekeeping gene for
normalisation in colorectal cancer experiments? Br J Cancer.
103:1475–1476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Colell A, Green DR and Ricci JE: Novel
roles for GAPDH in cell death and carcinogenesis. Cell Death
Differ. 16:1573–1581. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Altenberg B and Greulich KO: Genes of
glycolysis are ubiquitously overexpressed in 24 cancer classes.
Genomics. 84:1014–1020. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo C, Liu S and Sun MZ: Novel insight
into the role of GAPDH playing in tumor. Clin Transl Oncol.
15:167–172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hadzisejdić I, Mustać E, Jonjić N,
Petković M and Grahovac B: Nuclear EGFR in ductal invasive breast
cancer: Correlation with cyclin-D1 and prognosis. Mod Pathol.
23:392–403. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Courjal F, Cuny M, Simony-Lafontaine J,
Louason G, Speiser P, Zeillinger R, Rodriguez C and Theillet C:
Mapping of DNA amplifications at 15 chromosomal localizations in
1875 breast tumors: Definition of phenotypic groups. Cancer Res.
57:4360–4367. 1997.PubMed/NCBI
|
|
32
|
Mylona E, Tzelepis K, Theohari I,
Giannopoulou I, Papadimitriou C and Nakopoulou L: Cyclin D1 in
invasive breast carcinoma: Favourable prognostic significance in
unselected patients and within subgroups with an aggressive
phenotype. Histopathology. 62:472–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Watson DM, Elton RA, Jack WJ, Dixon JM,
Chetty U and Miller WR: The H-ras oncogene product p21 and
prognosis in human breast cancer. Breast Cancer Res Treat.
17:161–169. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moon A, Kim MS, Kim TG, Kim SH, Kim HE,
Chen YQ and Kim HR: H-ras, but not N-ras, induces an invasive
phenotype in human breast epithelial cells: A role for MMP-2 in the
H-ras-induced invasive phenotype. Int J Cancer. 85:176–181. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yong HY, Hwang JS, Son H, Park HI, Oh ES,
Kim HH, Kim DK, Choi WS, Lee BJ, Kim HR and Moon A: Identification
of H-Ras-specific motif for the activation of invasive signaling
program in human breast epithelial cells. Neoplasia. 13:98–107.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Malkas LH, Herbert BS, Abdel-Aziz W,
Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L,
Arnold RJ, et al: A cancer-associated PCNA expressed in breast
cancer has implications as a potential biomarker. Proc Natl Acad
Sci USA. 103:19472–19477. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bukholm IR, Bukholm G, Holm R and Nesland
JM: Association between histology grade, expression of HsMCM2, and
cyclin A in human invasive breast carcinomas. J Clin Pathol.
56:368–373. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee JS, Kim HS, Jung JJ, Kim YB, Park CS
and Lee MC: Correlation between angiogenesis, apoptosis and cell
proliferation in invasive ductal carcinoma of the breast and their
relation to tumor behavior. Anal Quant Cytol Histol. 23:161–168.
2001.PubMed/NCBI
|
|
39
|
Aziz SA, Pervez S, Khan SM, Kayani N and
Nasir MI: Prognostic value of proliferating cell nuclear antigen
(PCNA) in infiltrating ductal carcinoma breast. J Coll Physicians
Surg Pak. 15:225–229. 2005.PubMed/NCBI
|
|
40
|
Yu YL, Chou RH, Liang JH, Chang WJ, Su KJ,
Tseng YJ, Huang WC, Wang SC and Hung MC: Targeting the EGFR/PCNA
signaling suppresses tumor growth of triple-negative breast cancer
cells with cell-penetrating PCNA peptides. PLoS One. 8:e613622013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Turner N, Moretti E, Siclari O, Migliaccio
I, Santarpia L, D'Incalci M, Piccolo S, Veronesi A, Zambelli A, Del
Sal G and Di Leo A: Targeting triple negative breast cancer: Is p53
the answer? Cancer Treat Rev. 39:541–550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dey N, Barwick BG, Moreno CS,
Ordanic-Kodani M, Chen Z, Oprea-Ilies G, Tang W, Catzavelos C,
Kerstann KF, Sledge GW Jr, et al: Wnt signaling in triple negative
breast cancer is associated with metastasis. BMC Cancer.
13:5372013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Poage GM, Hartman ZC and Brown PH:
Revealing targeted therapeutic opportunities in triple-negative
breast cancers: A new strategy. Cell Cycle. 12:2705–2706. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
